Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
NOVEL SUBSTITUTED MACROHETEROCYCLIC COMPOUNDS AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/179600
Kind Code:
A1
Abstract:
Disclosed in the present invention are novel substituted macroheterocyclic compounds, which can be used as inhibitors for targets such as ALK mutations, or ALK mutation related signaling pathways, for example NTRKs, ROS1, BRAF, c-MET, EGFR/HER2, KRAS/MEK, PIK3CA, FDFR, DDR2 and/or VEGFR, PI3K, CDKs and PARP. Specifically disclosed are compounds represented by formula (I), or pharmaceutically acceptable salts, solvates, hydrates, isotope substitutes, or isomers thereof. The compounds having structures of the formula (I) have an inhibition effect on targets such as ALK mutations, NTRKs and ROS1, and particularly have a strong inhibition effect on ALK composite mutant protein (such as L1196M/G1202R), and therefore can be used for preparing drugs or molecular probes used for preventing or treating diseases (such as cancer and immune diseases) that are related to ALK mutations (especially composite mutations), and NTRKs, ROS1, BRAF, c-MET, EGFR/HER2, KRAS/MEK, PIK3CA, FDFR, DDR2 and/or VEGFR, PI3K, CDKs and PARP signaling pathways.

Inventors:
ZHANG LONG (CN)
NIU ZHANGMING (CN)
Application Number:
PCT/CN2023/082758
Publication Date:
September 28, 2023
Filing Date:
March 21, 2023
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
MINDRANK AI LTD (CN)
International Classes:
C07D491/18; A61K31/437; A61K31/439; A61K31/5383; A61P35/00; C07D491/12; C07D497/18; C07D498/12; C07D498/18; C07D498/22
Domestic Patent References:
WO2021226269A12021-11-11
WO2021226208A22021-11-11
WO2021027503A12021-02-18
WO2020257165A12020-12-24
WO2019126122A12019-06-27
Foreign References:
CN104513253A2015-04-15
Attorney, Agent or Firm:
BEIJING ORIGINTELLIGENCE IP LAW FIRM et al. (CN)
Download PDF: